Abstract:Background Numerous experiments and clinical practices have demonstrated the effectiveness of Qishen Yiqi dripping pills (QSYQ) on myocardial ischemia (MI). However, the bioactive ingredients and mechanisms remain unclear, leading to huge gaps between quality control and biological effect of QSYQ. Discovering quality markers (Q-markers) based on effective components is crucial for ensuring stable quality and clinical effectiveness of QSYQ. Purpose To explore Q-markers of QSYQ against MI by a stepwise strategy integrating serum pharmacochemistry, network pharmacology, metabolomics, quantitative analysis, and cell experiments. Methods Firstly, liquid/gas chromatography-mass spectrometry was applied to characterize chemical profiles of QSYQ in vitro and in vivo . Based on the serum migrating constituents, a component-target-MI interaction network was constructed. Subsequently, pharmacodynamics and metabolomics were conducted to evaluate cardioprotective effect and potential mechanism of QSYQ. Next, conjoint analysis of network pharmacology and metabolomics was performed to screen candidate Q-markers. Finally, the measurability and bioactivity were validated to justify their usage as Q-markers. Results A total of 97 components were identified in QSYQ, 24 prototypes of which were detected in serum. The "component-target-disease" interaction network was constructed based on serum migrating constituents. Pharmacodynamic results showed that QSYQ effectively improved cardiac function, attenuated inflammatory cell infiltration, alleviated myocardial fibrosis, and reduced the levels of myocardial enzymes and oxidative stress in MI rats. Metabolomics study demonstrated that 59 metabolites were markedly altered in MI rats, 25 of which were significantly reversely regulated by QSYQ. After integrative analysis of network pharmacology and metabolomics, 12 components were selected as candidate Q-markers of QSYQ, and the contents were quantified. These candidate Q-markers displayed synergistic protective effects against H 2 O 2 -induced injury in H9c2 cells. Taken together, 12 components with properties of transitivity and traceability, effectiveness, measurability, and compatibility contribution were defined as representative Q-markers of QSYQ, including Astragaloside IV, Ononin, Calycosin, Formononetin, Rosmarinic acid, Cryptotanshinone, Salvianolic acid A, Tanshinol, Ginsenoside Rb1, Ginsenoside Rg1, Nerolidol, and Santalol. Conclusion In this study, a novel stepwise integrated strategy was presented for discovering Q-markers related to therapeutic effects of traditional Chinese medicine prescriptions. Twelve comprehensive and representative Q-markers of QSYQ were identified for the first time to improve its quality control.

Quality assessment and Q‐markers discovery in Citri Sarcodactylis Fructus by integrating serum pharmacochemistry and network pharmacology

Identification of Quality Markers in Schisandra chinensis (Turcz.) Baill. Using UPLC-Q-Extractive Orbitrap/MS, Chemometric Analysis, and Network Pharmacology

Analysis of the characteristic compounds of Citri Sarcodactylis Fructus from different geographical origins

Discovery of quality markers in the rhizome of Atractylodes chinensis using GC–MS fingerprint and network pharmacology

UPLC-Q-Exactive Orbitrap MS Analysis for Identification of Lipophilic Components in Citri Sarcodactylis Fructus from Different Origins in China Using Supercritical CO2 Fluid Extraction Method.

A stepwise integrated strategy to explore quality markers of Qishen Yiqi dripping pills against myocardial ischemia

A multidimensional strategy for uncovering comprehensive quality markers of Schisandra chinensis (Turcz.) Baill based on pharmacodynamics and chemical properties

An Integrative Strategy for Discriminating Quality Markers of Tibetan Medicine Chebulae Fructus Based on Multidimensional Feature Network

An integrated approach to uncover quality markers of Traditional Chinese medicine underlying chemical profiling, network target selection and metabolomics approach: Guan-Xin-Jing capsule as a model

Discovery of Minor Quality Evaluation Marker Compounds for Chinese Patent Medicine Products Using a Two-Leveled Metabolomics Strategy

An Integrated Strategy for Ascertaining Quality Marker of Schisandra Chinensis (turcz.) Baill Based on Correlation Analysis Between Depression-Related Monoaminergic Metabolites and Chemical Components Profiling.

UHPLC-Q/Orbitrap HRMS combined with spectrum–effect relationship and network pharmacology to discovery the gastrointestinal motility–promoting material basis in Citri Sarcodactylis Fructus

Screening and Characterizing the Quality Markers of Selaginella Tamariscina (P. Beauv.) Spring Using Metabonomics and Molecular Networking

A funnel-type stepwise filtering strategy for identification of potential Q-markers of traditional Chinese medicine formulas

[Identification of Q-markers for Schisandrae Sphenantherae Fructus in treating drug-induced liver injury based on network pharmacology, fingerprint and quantitative analysis]

A New Concept on Quality Marker for Quality Assessment and Process Control of Chinese Medicines

A stepwise integrated multi-system to screen quality markers of Chinese classic prescription Qingzao Jiufei decoction on the treatment of acute lung injury by combining 'network pharmacology-metabolomics-PK/PD modeling'

Quantitative ternary network-oriented discovery of Q-markers from traditional Chinese medicine prescriptions: Bu-Zhong-Yi-Qi-Tang as a case study

Approaches to establish Q-markers for the quality standards of traditional Chinese medicines

Identifying potential Q-markers for quality evaluation of Zhenyuan capsule by integrating chemical analysis, network pharmacology, molecular docking, and molecular dynamics simulations

A novel and comprehensive strategy for quality control in complex Chinese medicine formula using UHPLC-Q-Orbitrap HRMS and UHPLC-MS/MS combined with network pharmacology analysis: Take Tangshen formula as an example